CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the ...

Great news for Tempus AI stock! The company has just received FDA approval for an upgraded version of its Tempus Pixel platform — a cardiac imaging system that uses advanced AI to deliver highly ...

A dozen years after taking Groupon public, billionaire Eric Lefkofsky is listing Tempus, built on a massive trove of AI-trained health data. Five years ago, Chicago-based billionaire and serial ...

Tempus AI, Inc. is projected to achieve 30% YoY top line growth in Q4 2024 as presented in management's preliminary results. Growth is forecast to continue in the 23-25% range in eFY25. Tempus is ...

Revenue of approximately ~$367 million, an increase of approximately 83% year-over-year Diagnostics revenue of ~$266 million, representing ~121% growth year-over-year, driven by Oncology volume growth ...

Tempus AI hopes to leverage artificial intelligence and its massive data set to improve outcomes for patients. It has partnered with nearly all of the top oncology companies. The company grew its ...